| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
U.S. net product sales of FILSPARI® totaled $200 million, representing 120% growth year-over-year; 1,932 new PSFs received during the quarter |
| 21 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
THIS EMPLOYMENT AGREEMENT is entered into by and between Travere Therapeutics, Inc., a Delaware corporation (hereinafter the “Company”), and Bradley Campbell (hereinafter “Executive”). |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Strong FSGS launch and continued IgAN growth drive robust FILSPARI demand; 2,012 new PSFs received during the second quarter |
| 09 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On July 6, 2026, Sandra Calvin, chief accounting officer (CAO) and principal accounting officer (PAO) of the Company, provided notice to the Company of her intention to retire from employment with the Company following the filing of the ... |
| 16 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On June 12, 2026, William Rote, Ph.D., Chief Research Officer of the Company, provided notice to the Company of his intention to retire from employment with the Company, effective February 17, 2027 (the “Retirement Date”), the 10 year an... |
| 02 Jun 2026 |
8-K: Entry into a Material Definitive Agreement
On June 1, 2026, Travere Therapeutics, Inc. (the “Company”) entered into a license and collaboration agreement (the “Agreement”) with Everest Medicines (Singapore) Pte. Ltd. (“Everest”), pursuant to which Everest grants an exclusive lice... |
| 21 May 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a)Successor to and Continuation of Prior Plans. The Plan is intended as the successor to and continuation of the Travere Therapeutics, Inc. 2015 Equity Incentive Plan (the “2015 Plan”) and the Travere Therapeutics, Inc. 2014 Incentive C... |
| 11 May 2026 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation +2 more
INDENTURE, dated as of May 11, 2026, among TRAVERE THERAPEUTICS, INC., a Delaware corporation (the “Company”), and U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as trustee (the “Trustee”): |
| 04 May 2026 |
8-K: Results of Operations and Financial Condition
FILSPARI achieved record 993 new PSFs for IgAN in the U.S. in the first quarter; U.S. net product sales grew 88% year-over-year to $105 million |
| 14 Apr 2026 |
8-K: Other Events
On April 13, 2026, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has approved FILSPARI® (sparsentan) to reduce proteinuria in adult and pediatric patients aged 8 years and older w... |
| 19 Feb 2026 |
8-K: Results of Operations and Financial Condition
U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter |
| 13 Jan 2026 |
8-K: Other Events
On January 13, 2026, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has extended the review timeline of its supplemental New Drug Application (“sNDA”) for FILSPARI® (sparsentan) in... |
| 12 Jan 2026 |
8-K: Results of Operations and Financial Condition
U.S. FILSPARI reaches all-time highs of 908 new PSFs and net product sales of approximately $103 million in 4Q 2025 |
| 30 Oct 2025 |
8-K: Results of Operations and Financial Condition
U.S. net product sales of FILSPARI® (sparsentan) grew 155% year-over-year to $90.9 million in 3Q 2025; 731 new PSFs received during the quarter |
| 10 Sep 2025 |
8-K: Other Events
On September 10, 2025, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has informed the Company that following further review of the supplemental New Drug Application (“sNDA”) for F... |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
U.S. net product sales of FILSPARI® (sparsentan) grew 165% year-over-year to $71.9 million in 2Q 2025; 745 new PSFs received in the quarter |
| 16 May 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
(a)Successor to and Continuation of Prior Plans. The Plan is intended as the successor to and continuation of the Travere Therapeutics, Inc. 2015 Equity Incentive Plan (the “2015 Plan”) and the Travere Therapeutics, Inc. 2014 Incentive C... |
| 15 May 2025 |
8-K: Other Events
On May 15, 2025, Travere Therapeutics, Inc. (the “Company”) announced that the U.S. Food and Drug Administration (“FDA”) has accepted its supplemental New Drug Application (“sNDA”) for traditional approval of FILSPARI® (sparsentan) for t... |
| 01 May 2025 |
8-K: Completion of Acquisition or Disposition of Assets
Submitted sNDA seeking full approval of FILSPARI® (sparsentan) for FSGS in March 2025 |
| 30 Apr 2025 |
8-K: Other Events
On April 29, 2025, Travere Therapeutics, Inc. (the “Company”) and CSL Vifor announced that the European Commission has approved the conversion of the conditional marketing approval (“CMA”) into a standard marketing authorization (“MA”) f... |
Loading...